Melanoma cells control antimelanoma CTL responses via interaction between TIGIT and CD155 in the effector phase

Journal of Investigative Dermatology

Volumn 136, Issue 1, 2016, Pages 255-263

  Inozume, Takashi ^a   Yaguchi, Tomonori ^b   Furuta, Junpei ^a   Harada, Kazutoshi ^c   Kawakami, Yutaka ^b   Shimada, Shinji ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD155 ANTIGEN; CD3 ANTIGEN; GAMMA INTERFERON; MELAN A; PROGRAMMED DEATH 1 LIGAND 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CTAG2 PROTEIN, HUMAN; CYTOKINE; IMMUNOGLOBULIN RECEPTOR; LEUKOCYTE ANTIGEN; MEMBRANE ANTIGEN; ORGANIC CATION TRANSPORTER; POLIOVIRUS RECEPTOR; SLC44A1 PROTEIN, HUMAN; SMALL INTERFERING RNA; TIGIT PROTEIN, HUMAN; TUMOR MARKER; VIRUS RECEPTOR;

ARTICLE; CELL CYCLE CHECKPOINT; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; EFFECTOR CELL; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; STABLE EXPRESSION; T CELL IMMUNORECEPTOR WITH IG AND ITIM DOMAIN; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION; ANTIGEN PRESENTING CELL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MELANOMA; METABOLISM; PATHOLOGY; SKIN TUMOR; TUMOR CELL CULTURE;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; BIOMARKERS, TUMOR; CYTOKINES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE ACTIVATION; MELANOMA; ORGANIC CATION TRANSPORT PROTEINS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, VIRUS; RNA, SMALL INTERFERING; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 84960158903     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/JID.2015.404     Document Type: Article

References (30)

1. Ahmadzadeh M, Johnson LA, Heemskerk B, Dudley ME, White DE, Rosenberg SA, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114: 1537-44.
2. Brahmer JR, Tykodi SS, Chow LQ, Pardoll DM, Gupta A, Wigginton JM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-65.
3. Casado JG, Pawelec G, Morgado S, Duran E, Solana R, Tarazona R, et al. Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol Immunother 2009; 58: 1517-26.
4. Chan CJ, Andrews DM, McLaughlin NM, Gilfillan S, Colonna M, Smyth MJ, et al. DNAM-1/CD155 interactions promote cytokine and NK cellmediated suppression of poorly immunogenic melanoma metastases. J Immunol 2010; 184: 902-11.
5. Chan CJ, Andrews DM, Smyth MJ. Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer. Curr Opin Immunol 2012; 24: 246-51.
6. Chauvin JM, Pagliano O, Fourcade J, Maurer M, Korman AJ, Zarour HM, et al. TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J Clin Invest 2015; 125: 2046-58.
7. Furuta J, Inozume T, Harada K, Shimada S. CD271 on melanoma cell is an IFN-gamma-inducible immunosuppressive factor that mediates downregulation of melanoma antigens. J Invest Dermatol 2014; 134: 1369-77.
8. Goding SR, Wilson KA, Xie Y, Tamada K, Strome SE, Antony PA, et al. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol 2013; 190: 4899-909.
9. Gros A, Robbins PF, Yao X, Douek DC, Yang JC, Rosenberg SA, et al. PD-1 identifies the patientespecific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Invest 2014; 124: 2246-59.
10. Hamid O, Robert C, Daud A, Li XN, Kang SP, Ribas A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-44.
11. Hodi FS, O'Day SJ, McDermott DF, Nichol GM, Hoos A, Urba WJ, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
12. Iguchi-Manaka A, Kai H, Yamashita Y, Kikutani H, Shibuya K, Shibuya A, et al. Accelerated tumor growth in mice deficient in DNAM-1 receptor. J Exp Med 2008; 205: 2959-64.
13. Inozume T, Hanada K, Wang QJ, Wunderlich JR, Rosenberg SA, Yang JC, et al. Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J Immunother 2010; 33: 956-64.
14. Johnson LA, Morgan RA, Dudley ME, Nathan DA, Laurencot CM, Rosenberg SA, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114: 535-46.
15. Johnston RJ, Comps-Agrar L, Hackney J, Irving B, Eaton DL, Grogan JL, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 2014; 26: 923-37.
16. Joller N, Hafler JP, Brynedal B, Levin SD, Sharpe AH, Kuchroo VK, et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol 2011; 186: 1338-42.
17. Levin SD, Taft DW, Brandt CS, Ramsdell F, Blazar BR, Lewis KE, et al. Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur J Immunol 2011; 41: 902-15.
18. Lozano E, Dominguez-Villar M, Kuchroo V, Hafler DA. The TIGIT/CD226 axis regulates human T cell function. J Immunol 2012; 188: 3869-75.
19. Palmer DC, Chan CC, Gattinoni L, Nussenblatt RB, Rosenberg SA, Restifo NP, et al. Effective tumor treatment targeting a melanoma/melanocyteassociated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci USA 2008; 105: 8061-6.
20. Pardoll DM The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64.
21. Robert C, Thomas L, Bondarenko I, Humphrey R, Hoos A, Wolchok JD, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-26.
22. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009; 21: 233-40.
23. Seth S, Ravens I, Lee CW, Forster R, Bernhardt G, Koenecke C, et al. Absence of CD155 aggravates acute graft-versus-host disease. Proc Natl Acad Sci USA 2011; 108: E32-3; author reply E4.
24. Stanietsky N, Simic H, Arapovic J, Tsukerman P, Jonjic S, Mandelboim O, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci USA 2009; 106: 17858-63.
25. Tahara-Hanaoka S, Miyamoto A, Hara A, Honda S, Shibuya K, Shibuya A. Identification and characterization of murine DNAM-1 (CD226) and its poliovirus receptor family ligands. Biochem Biophys Res Commun 2005; 329: 996-1000.
26. Tahara-Hanaoka S, Shibuya K, Kai H, Ohkochi N, Honda S, Shibuya A, et al. Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor. Blood 2006; 107: 1491-6.
27. Topalian SL, Hodi FS, Brahmer JR, Gupta A, Wigginton JM, Sznol M, et al. Safety, activity, and immune correlates of antiePD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54.
28. Wang QJ, Hanada K, Perry-Lalley D, Karpova T, Khong HT, Yang JC, et al. Generating renal cancer-reactive T cells using dendritic cells (DCs) to present autologous tumor. J Immunother 2005; 28: 551-9.
29. Wolchok JD, Kluger H, Callahan MK, Wigginton JM, Gupta A, Sznol M, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-33.
30. Yu X, Harden K, Gonzalez LC, Clark H, Eaton D, Grogan JL, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 2009; 10: 48-57.